| Arsenic | Health-Based | N/A | 0.016 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Eye and nose irritation; stomach discomfort |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jul 1, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jul 1, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jul 1, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jul 1, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jul 1, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jul 1, 2024 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Jun 30, 2024 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Jun 30, 2024 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Jun 30, 2024 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Jun 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.019 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Jun 21, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 21, 2024 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Mar 31, 2024 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Mar 31, 2024 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Mar 31, 2024 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Mar 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Dec 31, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Dec 31, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Dec 31, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Dec 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 18 | Sep 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 18 | Sep 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 18 | Sep 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 18 | Sep 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.012 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Radium (-226 and -228) | Health-Based | N/A | 10 | Sep 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 25 | Sep 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 25 | Sep 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 25 | Sep 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 25 | Sep 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 25 | Sep 30, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 10 | Sep 30, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 10 | Sep 30, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 10 | Sep 30, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 10 | Sep 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Jun 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Jun 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Jun 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Jun 30, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 34 | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 34 | Jun 30, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 13 | Jun 30, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 13 | Jun 30, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 13 | Jun 30, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 13 | Jun 30, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 13 | Jun 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 34 | Jun 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 34 | Jun 30, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 34 | Jun 30, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 22, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 22, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 18 | Mar 31, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 18 | Mar 31, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 18 | Mar 31, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 18 | Mar 31, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 18 | Mar 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 44 | Mar 31, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Mar 31, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Mar 31, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Mar 31, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Mar 31, 2023 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Mar 31, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 44 | Mar 31, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 44 | Mar 31, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 44 | Mar 31, 2023 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 44 | Mar 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 12, 2023 | Active | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 19 | Dec 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 19 | Dec 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 19 | Dec 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 19 | Dec 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 19 | Dec 31, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Dec 31, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Dec 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Dec 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.019 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.019 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Dec 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.019 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Dec 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 46 | Dec 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 46 | Dec 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 46 | Dec 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 46 | Dec 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 46 | Dec 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 21, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 21, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 18, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Sep 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Sep 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Sep 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Sep 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 16 | Sep 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 52 | Sep 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 52 | Sep 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 52 | Sep 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 52 | Sep 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 52 | Sep 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Radium (-226 and -228) | Health-Based | N/A | 17 | Jun 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 17 | Jun 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 56 | Jun 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 56 | Jun 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 56 | Jun 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 56 | Jun 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 56 | Jun 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 17 | Jun 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 17 | Jun 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 17 | Jun 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 11, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 11, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Radium (-226 and -228) | Health-Based | N/A | 18 | Mar 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 60 | Mar 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 60 | Mar 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 60 | Mar 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 60 | Mar 31, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 18 | Mar 31, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 18 | Mar 31, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 18 | Mar 31, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 18 | Mar 31, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 60 | Mar 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 59 | Dec 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Dec 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Dec 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Dec 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Dec 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Dec 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 59 | Dec 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 59 | Dec 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 59 | Dec 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 59 | Dec 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Toluene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| trans-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Toluene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Toluene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| o-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| o-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| o-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| o-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-Dichloropropane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-Dichloropropane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-Dichloropropane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-Dichloropropane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2,4-Trichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2,4-Trichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2,4-Trichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2,4-Trichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Ethylbenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Ethylbenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Toluene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Ethylbenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Vinyl chloride | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Increased risk of cancer |
| Vinyl chloride | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Increased risk of cancer |
| Vinyl chloride | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Increased risk of cancer |
| Vinyl chloride | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Increased risk of cancer |
| Carbon tetrachloride | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Carbon tetrachloride | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Carbon tetrachloride | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Carbon tetrachloride | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Trichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Trichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Trichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Trichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Tetrachloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Tetrachloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Tetrachloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Tetrachloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Liver problems; increased risk of cancer |
| Benzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Anemia; decrease in blood platelets; increased risk of cancer |
| Benzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Anemia; decrease in blood platelets; increased risk of cancer |
| Benzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Anemia; decrease in blood platelets; increased risk of cancer |
| Benzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Anemia; decrease in blood platelets; increased risk of cancer |
| cis-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| cis-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| cis-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| cis-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Xylenes, Total | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Xylenes, Total | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Xylenes, Total | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Xylenes, Total | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| DICHLOROMETHANE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| DICHLOROMETHANE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| DICHLOROMETHANE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| DICHLOROMETHANE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| p-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| p-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| p-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| p-Dichlorobenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| trans-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| trans-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| trans-1,2-Dichloroethylene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-Dichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1,1-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1,1-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1,1-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1,1-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1,2-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1,2-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1,2-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,1,2-Trichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Styrene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Styrene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Styrene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Styrene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| CHLOROBENZENE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| CHLOROBENZENE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| CHLOROBENZENE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| CHLOROBENZENE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-Dichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-Dichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-Dichloroethane | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Ethylbenzene | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| ETHYLENE DIBROMIDE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| ETHYLENE DIBROMIDE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| 1,2-DIBROMO-3-CHLOROPROPANE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| ETHYLENE DIBROMIDE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| ETHYLENE DIBROMIDE | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 22, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 22, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 54 | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Sep 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 54 | Sep 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 54 | Sep 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 54 | Sep 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 54 | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 22, 2021 | Active | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Jun 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Jun 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Jun 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 17 | Jun 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.018 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 52 | Jun 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 52 | Jun 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Jun 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Jun 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Jun 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Jun 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Jun 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 52 | Jun 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 52 | Jun 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 52 | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Mar 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Mar 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Mar 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 16 | Mar 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Mar 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Mar 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Mar 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Mar 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.018 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Radium (-226 and -228) | Health-Based | N/A | 19 | Mar 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.018 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 54 | Mar 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 54 | Mar 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 54 | Mar 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 54 | Mar 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.013 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Health-Based | N/A | 54 | Mar 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Public Notice | Monitoring | N/A | N/A | Mar 14, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 14, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |